[go: up one dir, main page]

NO20044049L - Fremstilling av N1-(2`-pyridyl)-1,2-propandiaminsulfaminsyre og den anvendelse ved syntese av biologisk aktive piperaziner - Google Patents

Fremstilling av N1-(2`-pyridyl)-1,2-propandiaminsulfaminsyre og den anvendelse ved syntese av biologisk aktive piperaziner

Info

Publication number
NO20044049L
NO20044049L NO20044049A NO20044049A NO20044049L NO 20044049 L NO20044049 L NO 20044049L NO 20044049 A NO20044049 A NO 20044049A NO 20044049 A NO20044049 A NO 20044049A NO 20044049 L NO20044049 L NO 20044049L
Authority
NO
Norway
Prior art keywords
propanediaminesulfamic
pyridyl
synthesis
preparation
acid
Prior art date
Application number
NO20044049A
Other languages
English (en)
Inventor
Gregg Brian Feigelson
Joseph Zeldis
Anita Wai-Yin Chan
Ivo Jirkovsky
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20044049L publication Critical patent/NO20044049L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20044049A 2002-03-12 2004-09-24 Fremstilling av N1-(2`-pyridyl)-1,2-propandiaminsulfaminsyre og den anvendelse ved syntese av biologisk aktive piperaziner NO20044049L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36345702P 2002-03-12 2002-03-12
PCT/US2003/007228 WO2003078396A1 (en) 2002-03-12 2003-03-10 Preparation of n1-(2’-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines

Publications (1)

Publication Number Publication Date
NO20044049L true NO20044049L (no) 2004-09-24

Family

ID=28041771

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044049A NO20044049L (no) 2002-03-12 2004-09-24 Fremstilling av N1-(2`-pyridyl)-1,2-propandiaminsulfaminsyre og den anvendelse ved syntese av biologisk aktive piperaziner

Country Status (27)

Country Link
US (1) US6784294B2 (no)
EP (2) EP1801103B1 (no)
JP (1) JP4397693B2 (no)
KR (1) KR20040091720A (no)
CN (1) CN100341854C (no)
AR (1) AR038932A1 (no)
AT (2) ATE449073T1 (no)
AU (1) AU2003220122A1 (no)
BR (1) BR0308315A (no)
CA (1) CA2477886A1 (no)
CY (1) CY1106677T1 (no)
DE (2) DE60330199D1 (no)
DK (1) DK1483243T3 (no)
EC (1) ECSP045291A (no)
ES (2) ES2283762T3 (no)
HK (1) HK1068618A1 (no)
IL (1) IL163829A0 (no)
MX (1) MXPA04008731A (no)
NO (1) NO20044049L (no)
NZ (1) NZ535170A (no)
PT (1) PT1483243E (no)
RU (1) RU2314294C2 (no)
SI (1) SI1483243T1 (no)
TW (1) TWI288642B (no)
UA (1) UA80272C2 (no)
WO (1) WO2003078396A1 (no)
ZA (1) ZA200408213B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060223824A1 (en) 2000-11-28 2006-10-05 Wyeth Serotonergic agents
WO2003007956A1 (en) * 2001-07-20 2003-01-30 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
TW200304825A (en) * 2002-03-12 2003-10-16 Wyeth Corp Process for making chiral 1,4-disubstituted piperazines
MXPA04008731A (es) 2002-03-12 2004-12-06 Wyeth Corp Preparacion de acido n1-(2¦-piridil)-1,2-propanodiamino sulfamico y su uso en la sintesis de piperazinas biologicamente activas.
US7361773B2 (en) * 2002-03-12 2008-04-22 Wyeth Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
PA8626301A1 (es) * 2004-03-19 2006-12-07 Wyeth Wyeth Proceso para preparar derivados de n-aril-piperazina
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US20070099931A1 (en) * 2004-03-19 2007-05-03 Wyeth Pharmaceutical dosage forms and compositions
TW200700413A (en) * 2005-03-01 2007-01-01 Wyeth Corp Crystalline and amorphous 4-cyano-n-{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride
CN104072483B (zh) 2010-03-12 2016-04-13 日本曹达株式会社 含有吡啶环的化合物、及卤代甲基吡啶衍生物以及四唑基肟衍生物的制造方法
EP2602248A1 (en) 2011-12-05 2013-06-12 University Of Leicester Novel pyrrole compounds
GB201310126D0 (en) * 2013-06-06 2013-07-24 Univ Leicester Novel pyrrole derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE81975T1 (de) * 1984-12-21 1992-11-15 Duphar Int Res Arzneimittel mit psychotroper wirkung.
JPH01125357A (ja) 1987-11-06 1989-05-17 Dainippon Pharmaceut Co Ltd トリペプチドの誘導体
MX9201991A (es) 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
JP3077047B2 (ja) 1993-04-16 2000-08-14 参天製薬株式会社 新規ピペラジン誘導体
AU2622595A (en) * 1994-06-03 1996-01-04 John Wyeth & Brother Limited Novel processes and intermediates for the preparation of piperazine derivatives
GB9411099D0 (en) 1994-06-03 1994-07-27 Wyeth John & Brother Ltd Piperazine derivatives
GB9514901D0 (en) * 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives
EP0901373B1 (en) 1996-04-10 2002-11-06 Merck & Co., Inc. Alpha v Beta 3 ANTAGONISTS
MXPA04008731A (es) 2002-03-12 2004-12-06 Wyeth Corp Preparacion de acido n1-(2¦-piridil)-1,2-propanodiamino sulfamico y su uso en la sintesis de piperazinas biologicamente activas.
WO2003078417A1 (en) * 2002-03-12 2003-09-25 Wyeth, A Corporation Of The State Of Delaware Process for synthesizing chiral n-aryl piperazines

Also Published As

Publication number Publication date
DK1483243T3 (da) 2007-08-06
ZA200408213B (en) 2007-03-28
BR0308315A (pt) 2004-12-28
WO2003078396A8 (en) 2004-01-29
US6784294B2 (en) 2004-08-31
CN100341854C (zh) 2007-10-10
EP1801103A1 (en) 2007-06-27
HK1068618A1 (en) 2005-04-29
JP2005526088A (ja) 2005-09-02
ES2334836T3 (es) 2010-03-16
DE60313301D1 (de) 2007-05-31
IL163829A0 (en) 2005-12-18
EP1483243B1 (en) 2007-04-18
JP4397693B2 (ja) 2010-01-13
US20030204087A1 (en) 2003-10-30
PT1483243E (pt) 2007-06-27
ATE360002T1 (de) 2007-05-15
ECSP045291A (es) 2004-10-26
RU2314294C2 (ru) 2008-01-10
AR038932A1 (es) 2005-02-02
AU2003220122A1 (en) 2003-09-29
ATE449073T1 (de) 2009-12-15
ES2283762T3 (es) 2007-11-01
UA80272C2 (en) 2007-09-10
MXPA04008731A (es) 2004-12-06
TWI288642B (en) 2007-10-21
DE60330199D1 (de) 2009-12-31
EP1801103B1 (en) 2009-11-18
NZ535170A (en) 2006-03-31
CY1106677T1 (el) 2012-05-23
DE60313301T2 (de) 2007-12-27
EP1483243A1 (en) 2004-12-08
WO2003078396A1 (en) 2003-09-25
CN1642916A (zh) 2005-07-20
TW200303751A (en) 2003-09-16
KR20040091720A (ko) 2004-10-28
RU2004130314A (ru) 2005-04-10
CA2477886A1 (en) 2003-09-25
SI1483243T1 (sl) 2007-08-31

Similar Documents

Publication Publication Date Title
ATE296302T1 (de) 4-(1,3,4-thiadiazolyl-2-yl)-1,4-diazabizyklo- 3.2.2 nonanderivate, ihre herstellung und ihre therapeutische verwendung
DE60233265D1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
NO2015009I1 (no) Nintedanib, tautomere og salter derav, spesielt Nintedanib og fysiologiske akseptable salter derav, spesielt Nintedanib esilat; 3-Z-[l-(4-(N-((4-metylpiperazin-1-yl)-metylkarbonyl)-N-metylamino)- anilino)-1-fenylmetylen]-6-metoksykarbonyl-2-indolinon - Se blant annet kravene 1, 2, 5 (t) og 6 i basispatentet
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
DE60107859D1 (de) Benzimidazolderivate, ihre herstellung und therapeutische verwendung
DK1329456T3 (da) Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme
HUP0302845A3 (en) 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical
DK1267880T4 (da) Entecavir-formulering med lav dosis og anvendelse deraf
DE602004022946D1 (de) 4-cyanopyrazol-3-carbonsäureamidderivate, herstellung und therapeutische anwendung davon
DE50202479D1 (de) Saure pigmentdispergatoren und pigmentzubereitungen
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
EE05243B1 (et) 4-(fenüülpiperasinüülmetüül)bensamiidi derivaadid, nende valmistamine ja kasutamine valu, ärevuse ja seedetrakti häirete ravis
DE60209486D1 (de) Pyranoindazole und ihre verwendung in der glaukombehandlung
DE60209929D1 (de) Succinate des 5,8,14-triazatetracycloä10.3.1.0 2,11 .0 4,9 ü-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
NO20044049L (no) Fremstilling av N1-(2`-pyridyl)-1,2-propandiaminsulfaminsyre og den anvendelse ved syntese av biologisk aktive piperaziner
ATE267201T1 (de) 4-(2-phenylthiazol-5-yl)1,4- diazabicyclo(3.2.2)nonanederivate, ihre herstellung und therapeutische verwendung
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
DE60208044D1 (de) Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung
IS6378A (is) Efnasambönd og samsetningar gegn dvergveirum, notkun þeirra til lyfjagerðar og efni til að framleiða þau
DE60204755D1 (de) "3,7-diazabicyclo(3.3.0)octane und deren verwendung bei der behandlung von herzrhythmusstörungen"
PL367676A1 (en) Novel heterocyclic derivatives and medicinal use thereof
PL367639A1 (en) Novel heterocyclic compound and medicinal use thereof
DE60217870D1 (de) Verwendung von 2- 5-(4-fluorphenyl)-3-pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze
ATE494278T1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application